What’s up everyone — here are three speculative Canadian microcaps I’m tracking this month. All are low-float, high-risk, and from totally different sectors: cybersecurity, biotech, and telehealth. Every number below is pulled directly from Yahoo Finance or official filings, and all USD figures have been converted to CAD. Let’s dive in.
1. Scope Technologies (CSE: SCPE / OTCQB: SCPCF)
Scope is developing quantum-resistant cybersecurity tech through its “QSE” suite, including secure messaging and file-sharing solutions tailored to industries like legal, financial, and healthcare.
In Q1 2025, Scope raised approximately C$2.8M through private placements and ramped up marketing via a U.S. agency. They’re aiming to roll out the QSE App and signed several master reseller agreements. As of June 2025, the stock trades at CA$0.415 according to Yahoo Finance, with a market cap of approximately CA$22.6M and an estimated float of 48–55 million shares.
Still early-stage with limited revenue, Scope’s upside is tied to broader interest in quantum security and AI-enabled privacy tools. A confirmed product launch or government/enterprise deal could be a catalyst.
2. NurExone Biologic (TSXV: NRX / OTCQB: NRXBF)
NurExone is advancing a non-invasive exosome-based drug delivery platform for neurological injuries. Its flagship therapy, ExoPTEN, targets spinal cord injury and is delivered via nasal spray. Their GMP-compliant Exo-Top facility in Nevada gives them end-to-end control.
Preclinical trials showed up to 75% motor recovery in rats, and the therapy has received Orphan Drug Designation. As of mid-June, Yahoo Finance lists the share price at CA$0.70, with a market cap around CA$55M and ~78M shares outstanding (~54M float).
The company was also named to the TSX Venture 50 for 2024 due to its market cap growth and share performance. Watch for updates on clinical trial timelines or U.S. uplisting developments.
3. Mangoceuticals (NASDAQ: MGRX)
Mangoceuticals markets men’s and women’s wellness treatments through MangoRx and PeachesRx. Their recent acquisition of oral pouch IP from Smokeless Technology and a new product line for GLP-1 weight-loss medications mark a major pivot.
They’ve filed a US$150M (≈ CA$203M) shelf prospectus to support expansion, though dilution is a risk. As of June 2025, the stock trades at US$2.02 (≈ CA$2.74), and Yahoo Finance shows a market cap of CA$23M with about 11M shares outstanding and an 8M float.
With minimal revenue (~CA$0.69M in FY 2024) and cash concerns flagged by auditors, it’s a speculative play — but new product traction could light a short-term fire.
Quick Comparison
| Ticker | Sector | Share Price (CAD) | Market Cap (CAD) | Catalyst | Risk | My Take |
|---|---|---|---|---|---|---|
| SCPE | Quantum Security | CA$0.415 | CA$22.6M | App launch, enterprise traction | High | Sector buzz potential, but needs delivery |
| NRX | Biotech | CA$0.70 | CA$55M | Clinical trial updates, uplisting | Very High | Biotech long shot, but structured platform |
| MGRX | Telehealth | CA$2.74 | CA$23M | Product launch, revenue beat | High | Event-driven; dilution and liquidity key |
If you’re watching any other low-float names, drop them in the comments.
Not financial advice. Just sharing my watchlist.
Marc has been involved in the Stock Market Media Industry for the last +5 years. After obtaining a college degree in engineering in France, he moved to Canada, where he created Money,eh?, a personal finance website.
